Sarepta Therapeutics (SRPT) Profit After Tax (2010 - 2026)

Sarepta Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $350.9 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 178.4% year-over-year to $350.9 million; the TTM figure through Mar 2026 stood at $85.0 million (up 134.2% YoY), while the FY2025 annual figure was -$713.4 million, down 403.27% from the prior year.
• Profit After Tax for Q1 2026 stood at $350.9 million, up from -$412.2 million in the prior quarter.
• The five-year high for Profit After Tax was $350.9 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
• The 5-year median for Profit After Tax is -$40.9 million (2023), against an average of -$80.2 million.
• Peak annual rise in Profit After Tax reached 2947.86% in 2025, while the deepest fall reached 1338.98% in 2025.
• Sarepta Therapeutics' Profit After Tax stood at -$106.1 million in 2022, then jumped by 143.05% to $45.7 million in 2023, then surged by 248.37% to $159.0 million in 2024, then slumped by 359.18% to -$412.2 million in 2025, then soared by 185.11% to $350.9 million in 2026.
• Business Quant data shows SRPT's Profit After Tax at $350.9 million in Q1 2026, -$412.2 million in Q4 2025, and -$50.6 million in Q3 2025.